{"id":"dalbavancin-via-intraperitoneal-administration","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Local peritoneal irritation"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Renal impairment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dalbavancin works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, similar to vancomycin but with enhanced potency and a longer half-life. When administered intraperitoneally, it achieves high local concentrations in the peritoneal cavity to treat intra-abdominal infections. The intraperitoneal route allows direct delivery to the infection site while minimizing systemic exposure.","oneSentence":"Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:32:07.095Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intra-abdominal infections via intraperitoneal administration"},{"name":"Peritonitis in peritoneal dialysis patients"}]},"trialDetails":[{"nctId":"NCT02940730","phase":"PHASE4","title":"Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-05-01","conditions":"Infectious Peritonitis","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dalbavancin via Intraperitoneal Administration","genericName":"Dalbavancin via Intraperitoneal Administration","companyName":"University of Colorado, Denver","companyId":"university-of-colorado-denver","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors. Used for Intra-abdominal infections via intraperitoneal administration, Peritonitis in peritoneal dialysis patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}